Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


X0202 SCHEDULE 13D/A 0001178913-26-004023 0000919590 XXXXXXXX LIVE 1 Ordinary shares, par value NIS 0.20 per share 08/11/2026 false 0001574565 M4119S187 Evogene Ltd. 13 Gad Feinstein Street, Park Rehovot Rehovot IL 7638517 Nitsan Deutsch 972-8-9311900 13 Gad Feinstein Street, Park Rehovot c/o Evogene Ltd. Rehovot IL 7638517 0000919590 N RECANATI LEON b PF N L3 1354836.00 0.00 1354836.00 0.00 1354836.00 N 8.6 IN (1) The percentage of Ordinary Shares beneficially owned by the Reporting Person is based on 15,801,407 Ordinary Shares outstanding as of July 27, 2026, as reported by the Issuer in the Issuer's Proxy Statement for its 2026 Annual General Meeting of Shareholders, dated July 31, 2026, attached as Exhibit 99.2 to the Issuer's Form 6-K that was furnished to the U.S. Securities and Exchange Commission on July 31, 2026. The aggregate beneficial ownership includes 10,950 Ordinary Shares underlying share options held by the Reporting Person that are currently exercisable or exercisable within 60 days of August 11, 2026. Ordinary shares, par value NIS 0.20 per share Evogene Ltd. 13 Gad Feinstein Street, Park Rehovot Rehovot IL 7638517 Leon Recanati (the "Reporting Person"). 27 Yoav St., Tel Aviv 6908165, Israel. Mr. Recanati serves as a member of the board of directors of Evogene Ltd. (the "Issuer"). Mr. Recanati is also the founder and principal of GlenRock Israel, a family office investment company that manages the investment activities of the Recanati family and invests primarily in companies engaged in technology, life sciences, cyber, and agritech. The address of Mr. Recanati's principal office and principal place of business is 85 Medinat Hayehudim Street, Tower G, 8th Floor, Herzliya Business Park, Herzliya 4676670, Israel. During the last five years, Mr. Recanati has not been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors). During the last five years, Mr. Recanati has not been a party to any civil proceeding of a judicial or administrative body of competent jurisdiction that resulted in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws. Mr. Recanati is a citizen of the State of Israel. Item 3 of the original Statement of Beneficial Ownership on Schedule 13D filed by the Reporting Person on August 11, 2026 (the "Original Statement") is hereby amended and supplemented by adding the following: On August 11, 2026, the Reporting Person purchased an additional 460,000 Ordinary Shares in open market transactions at a purchase price of $0.635 per share, for aggregate consideration of $292,100. The source of funds used to acquire those additional Ordinary Shares was the personal funds of the Reporting Person. Item 4 of the Original Statement is incorporated by reference herein and is furthermore hereby amended and supplemented by adding the following: On August 11, 2026, the Reporting Person purchased 460,000 Ordinary Shares. Except as set forth herein or in the Original Statement, the Reporting Person does not currently have any plans or proposals that relate to or would result in any of the transactions or other matters specified in subparagraphs (a) through (j) of Item 4 of Schedule 13D. As of the date of this Amendment No. 1 to the Original Statement, the Reporting Person beneficially owns an aggregate of 1,354,836 Ordinary Shares, representing approximately 8.6% of the outstanding Ordinary Shares of the Issuer, consisting of (i) 1,343,886 Ordinary Shares held directly, and (ii) 10,950 Ordinary Shares underlying share options that are currently exercisable or exercisable within 60 days of August 11, 2026. The percentage of Ordinary Shares beneficially owned by the Reporting Person is based on 15,801,407 Ordinary Shares outstanding as of July 27, 2026, as reported by the Issuer in the Issuer's Proxy Statement for its 2026 Annual General Meeting of Shareholders, dated July 31, 2026, attached as Exhibit 99.2 to the Issuer's Report of Foreign Private Issuer on Form 6-K that was furnished to the SEC on July 31, 2026. The Reporting Person has sole voting power and sole dispositive power with respect to all 1,354,836 Ordinary Shares beneficially owned by him, which are held directly by him (including 10,950 Ordinary Shares underlying share options that are currently exercisable or exercisable within 60 days of August 11, 2026). No other person has shared voting or dispositive power with respect to such shares. On August 11, 2026, the Reporting Person purchased an additional 460,000 Ordinary Shares of the Issuer in open market transactions at a price of $0.635 per share. Prior to this purchase, the Reporting Person had held 883,886 Ordinary Shares directly (besides shares underlying exercisable options). Not applicable. Not applicable. There are no contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Person and any other person with respect to any securities of the Issuer, including but not limited to the transfer or voting of any such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies. RECANATI LEON /s/ Leon Recanati Leon Recanati 08/13/2026